China Pilots Scheme To Halve IND Review Time For Innovative Drugs

 
• By Dexter Jie Yan

China’s top drug regulator is implementing a pilot program offering shorter review times for IND applications to improve the quality and efficiency of clinical studies and stimulate the country’s innovative drug sector.

shorten time
China looks to cut the IND review time for innovative drugs to 30 working days in a new pilot scheme. • Source: Shutterstock

More from China

More from Asia